Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
5.26
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
5.00
-0.26 (-4.94%)
After-hours: Apr 28, 2026, 6:45 PM EDT

Company Description

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.

The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis.

The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Journey Medical Corporation
Journey Medical logo
Country United States
Founded 2014
IPO Date Nov 12, 2021
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 58
CEO Claude Maraoui

Contact Details

Address:
9237 East Via de Ventura Blvd. , Suite 105
Scottsdale, Arizona 85258
United States
Phone 480 434 6670
Website journeymedicalcorp.com

Stock Details

Ticker Symbol DERM
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $10.00
CIK Code 0001867066
CUSIP Number 48115J109
ISIN Number US48115J1097
Employer ID 47-1879539
SIC Code 2834

Key Executives

Name Position
Claude Maraoui Founder, President, Chief Executive Officer and Director
Dr. Lindsay Allan Rosenwald M.D. Executive Chairman
Joseph M. Benesch Chief Financial Officer and Corporate Controller
Ramsey Alloush Chief Operating Officer, General Counsel and Company Secretary
Robert Nevin Chief Commercial Officer
Jaclyn Jaffe Senior Director of Corporate Operations
Louis Donati Director of Market Access

Latest SEC Filings

Date Type Title
Apr 21, 2026 8-K Current Report
Apr 6, 2026 SCHEDULE 13G/A Filing
Mar 26, 2026 10-K Annual Report
Mar 25, 2026 8-K Current Report
Jan 23, 2026 424B3 Prospectus
Jan 23, 2026 424B3 Prospectus
Jan 21, 2026 EFFECT Notice of Effectiveness
Jan 15, 2026 S-3 Registration statement under Securities Act of 1933
Dec 30, 2025 DRS [Cover] Draft Registration Statement
Nov 12, 2025 10-Q Quarterly Report